Search details
1.
A model for the return and referral of all clinically significant secondary findings of genomic sequencing.
J Med Genet
; 60(8): 733-739, 2023 08.
Article
in English
| MEDLINE | ID: mdl-37217257
2.
Great expectations: patients' preferences for clinically significant results from genomic sequencing.
Hum Genet
; 142(4): 553-562, 2023 Apr.
Article
in English
| MEDLINE | ID: mdl-36943453
3.
"I don't need any more unknowns hanging over my head": Views of patients with cancer on variants of uncertain significance and low/moderate risk results from genomic sequencing.
Genet Med
; 25(12): 100960, 2023 Dec.
Article
in English
| MEDLINE | ID: mdl-37577963
4.
How do members of the public expect to use variants of uncertain significance in their health care? A population-based survey.
Genet Med
; 25(5): 100819, 2023 05.
Article
in English
| MEDLINE | ID: mdl-36919843
5.
A comprehensive genomic reporting structure for communicating all clinically significant primary and secondary findings.
Hum Genet
; 141(12): 1875-1885, 2022 Dec.
Article
in English
| MEDLINE | ID: mdl-35739291
6.
"Game Changer": Health Professionals' Views on the Clinical Utility of Circulating Tumor DNA Testing in Hereditary Cancer Syndrome Management.
Oncologist
; 27(5): e393-e401, 2022 05 06.
Article
in English
| MEDLINE | ID: mdl-35385106
7.
"Doctors shouldn't have to cheat the system": Clinicians' real-world experiences of the utility of genomic sequencing.
Genet Med
; 24(9): 1888-1898, 2022 09.
Article
in English
| MEDLINE | ID: mdl-35612591
8.
Exome and genome sequencing in adults with undiagnosed disease: a prospective cohort study.
J Med Genet
; 58(4): 275-283, 2021 04.
Article
in English
| MEDLINE | ID: mdl-32581083
9.
The clinical utility of exome and genome sequencing across clinical indications: a systematic review.
Hum Genet
; 140(10): 1403-1416, 2021 Oct.
Article
in English
| MEDLINE | ID: mdl-34368901
10.
Beyond medically actionable results: an analytical pipeline for decreasing the burden of returning all clinically significant secondary findings.
Hum Genet
; 140(3): 493-504, 2021 Mar.
Article
in English
| MEDLINE | ID: mdl-32892247
11.
Patient and public preferences for being recontacted with updated genomic results: a mixed methods study.
Hum Genet
; 140(12): 1695-1708, 2021 Dec.
Article
in English
| MEDLINE | ID: mdl-34537903
12.
Clinical and psychological outcomes of receiving a variant of uncertain significance from multigene panel testing or genomic sequencing: a systematic review and meta-analysis.
Genet Med
; 23(1): 22-33, 2021 01.
Article
in English
| MEDLINE | ID: mdl-32921787
13.
Effect of genetics clinical decision support tools on health-care providers' decision making: a mixed-methods systematic review.
Genet Med
; 23(4): 593-602, 2021 04.
Article
in English
| MEDLINE | ID: mdl-33420345
14.
The role of digital tools in the delivery of genomic medicine: enhancing patient-centered care.
Genet Med
; 23(6): 1086-1094, 2021 06.
Article
in English
| MEDLINE | ID: mdl-33654192
15.
Effectiveness of the Genomics ADvISER decision aid for the selection of secondary findings from genomic sequencing: a randomized clinical trial.
Genet Med
; 22(4): 727-735, 2020 04.
Article
in English
| MEDLINE | ID: mdl-31822848
16.
Variant classification changes over time in BRCA1 and BRCA2.
Genet Med
; 21(10): 2248-2254, 2019 10.
Article
in English
| MEDLINE | ID: mdl-30971832
17.
Correction: Variant classification changes over time in BRCA1 and BRCA2.
Genet Med
; 21(10): 2406-2407, 2019 Oct.
Article
in English
| MEDLINE | ID: mdl-31043710
18.
"I just wanted more": Hereditary cancer syndromes patients' perspectives on the utility of circulating tumour DNA testing for cancer screening.
Eur J Hum Genet
; 32(2): 176-181, 2024 Feb.
Article
in English
| MEDLINE | ID: mdl-37821757
19.
Shared Decision Making in the Care of Patients With Cancer.
Am Soc Clin Oncol Educ Book
; 43: e389516, 2023 Jun.
Article
in English
| MEDLINE | ID: mdl-37339391
20.
Theory-based behavior change intervention to increase uptake of risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 pathogenic variant: The PREVENT randomized controlled trial.
Cancer Med
; 12(17): 18246-18257, 2023 09.
Article
in English
| MEDLINE | ID: mdl-37602539